Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 2:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 268 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: everolimus (RAD001) Clear all
Completed Phase 1 Interventional

A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma

NCT00422344
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
RAD001, Sunitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2010 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 1 Interventional

Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

NCT01548807
View directory record Official record
Conditions
Prostate Cancer Patients With Detectable PSA Following Prostatectomy
Interventions
Everolimus (RAD001)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 1 Interventional

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

NCT01197170
View directory record Official record
Conditions
Solid Tumors, Advanced Cancer
Interventions
Anastrozole, Bevacizumab, Everolimus, Sorafenib, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 11, 2026, 2:40 AM EDT
Terminated Phase 1 Interventional

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

NCT03878524
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Abemaciclib, Abiraterone, Afatinib, Bevacizumab, Bicalutamide, Biospecimen Collection, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, Carboplatin, Celecoxib, Cobimetinib, Copanlisib, Dabrafenib, Dacomitinib, Darolutamide, Dasatinib, Doxorubicin, Durvalumab, Enasidenib, Entrectinib, Enzalutamide, Erlotinib, Everolimus, Fluorouracil, Idelalisib, Imatinib, Ipilimumab, Lenvatinib, Leucovorin, Lorlatinib, Losartan, Nab-paclitaxel, Neratinib, Nivolumab, Olaparib, Oxaliplatin, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Ponatinib, Quality-of-Life Assessment, Regorafenib, Ruxolitinib, Sirolimus, Sorafenib, Sunitinib, Trametinib, Trastuzumab Emtansine, Tretinoin, Vemurafenib, Venetoclax, Vismodegib, Vorinostat
Drug · Biological · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 1 Interventional

A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007

NCT01061788
View directory record Official record
Conditions
Advanced Solid Tumors, Non-small Cell Lung Cancer
Interventions
AMG 479, Everolimus, Panitumumab
Drug
Lead sponsor
Jeffrey Clarke
Other
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 11, 2026, 2:40 AM EDT
Terminated Phase 1 Interventional Results available

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

NCT01642732
View directory record Official record
Conditions
Prostate Cancer
Interventions
Everolimus, lupron, bicalutamide, and radiation
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 1 Interventional

Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer

NCT02125084
View directory record Official record
Conditions
Prostate Cancer
Interventions
Everolimus, Enzalutamide
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
5
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 2 Interventional Results available

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

NCT00449748
View directory record Official record
Conditions
Systemic Mastocytosis
Interventions
RAD001 (Everolimus)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 2 Interventional Results available

Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

NCT02352844
View directory record Official record
Conditions
Solid Malignancy, Solid Tumor
Interventions
Everolimus
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex

NCT00411619
View directory record Official record
Conditions
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Interventions
Everolimus
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 2 Interventional Results available

Everolimus for Cancer With TSC1 or TSC2 Mutation

NCT02201212
View directory record Official record
Conditions
TSC1, TSC2, Tuberous Sclerosis Complex, MTOR
Interventions
Everolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 11, 2026, 2:40 AM EDT
Suspended Phase 2 Interventional

UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

NCT03139747
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Lenvatinib, Everolimus
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 11, 2026, 2:40 AM EDT
Terminated Phase 2 Interventional Results available

Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer

NCT00526591
View directory record Official record
Conditions
Prostate Cancer
Interventions
Everolimus, conventional surgery
Drug · Procedure
Lead sponsor
Jorge A. Garcia, MD
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

NCT01059318
View directory record Official record
Conditions
Lymphangioleiomyomatosis
Interventions
Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

NCT00085566
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Prostate Cancer
Interventions
everolimus, gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 1 Interventional

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

NCT00981162
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sorafenib tosylate, everolimus, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Aurora, Colorado • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 11, 2026, 2:40 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of RAD001 Head and Neck Cancer

NCT01051791
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Everolimus 10mg daily
Drug
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 11, 2026, 2:40 AM EDT
Recruiting Phase 2 Interventional

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

NCT05773274
View directory record Official record
Conditions
Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
Interventions
Biospecimen Collection, Cabozantinib, Computed Tomography, Everolimus, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Sunitinib
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)

NCT00789828
View directory record Official record
Conditions
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Interventions
Everolimus, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 4 Interventional Results available

Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus

NCT02338609
View directory record Official record
Conditions
Growth and Development
Interventions
Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Saint Paul, Minnesota • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 11, 2026, 2:40 AM EDT
Terminated Phase 2 Interventional Results available

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

NCT01239342
View directory record Official record
Conditions
Metastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Akt Inhibitor MK2206, Everolimus, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
8
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 11, 2026, 2:40 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

NCT00655252
View directory record Official record
Conditions
Metastatic Renal Cell Cancer
Interventions
Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
U.S. locations
15
States / cities
Springdale, Arkansas • Aurora, Colorado • Ocoee, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 11, 2026, 2:40 AM EDT
Completed Phase 2 Interventional Results available

Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer

NCT00985192
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
everolimus, laboratory biomarker analysis
Drug · Other
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
18
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 11, 2026, 2:40 AM EDT
Terminated Phase 2 Interventional Results available

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

NCT01185366
View directory record Official record
Conditions
Kidney Cancer
Interventions
Everolimus, Sunitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 11, 2026, 2:40 AM EDT